CONCLUSION: These data contribute to the understanding of the long-term safety of an extended-release stimulant in children 4 to < 6 years of age. The observed risk of a TEAE-related discontinuation was ∼11%. TEAEs were not dose-related and most were of mild to moderate severity. Symptom control was maintained through the year-long study.